-
公开(公告)号：US09657049B2
公开(公告)日：2017-05-23
申请号：US13673466
申请日：2012-11-09
IPC分类号： C12N15/113 , C07H21/02 , C07H21/04 , A61K38/00 , A61K48/00
CPC分类号： C07H21/04 , A61K38/00 , A61K48/00 , C12N15/113 , C12N2310/11 , C12N2310/3231 , C12N2320/33
摘要： Oligonucleotides having a nucleotide sequence complementary to nucleotide numbers such as 2571-2607, 2578-2592, 2571-2592, 2573-2592, 2578-2596, 2578-2601 or 2575-2592 of the dystrophin cDNA (Gene Bank accession No. NM_004006.1) and therapeutic agents for muscular dystrophy comprising such oligonucleotides.
-
公开(公告)号：US20070082861A1
公开(公告)日：2007-04-12
申请号：US10536258
申请日：2003-11-21
IPC分类号： A61K48/00 , C07H19/048 , C07H21/02
CPC分类号： C07H21/04 , A61K38/00 , A61K48/00 , C12N15/113 , C12N2310/11 , C12N2310/3231 , C12N2320/33
摘要： Oligonucleotides having a nucleotide sequence complementary to nucleotide numbers such as 2571-2607, 2578-2592, 2571-2592, 2573-2592, 2578-2596, 2578-2601 or 2575-2592 of the dystrophin cDNA (Gene Bank accession No. NM_004006.1) and therapeutic agents for muscular dystrophy comprising such oligonucleotides.
摘要翻译： 具有与核苷酸序列互补的核苷酸序列的寡核苷酸，例如抗肌萎缩蛋白cDNA（Gene Bank登录号NM_004006）的2571-2607,2578-2592,2571-2592,2573-2592,2578-2596,2578-2601或2575-2592。 1）和包含这种寡核苷酸的肌营养不良的治疗剂。
-
3.发明申请ENA NUCLEIC ACID PHARMACEUTICALS CAPABLE OF MODIFYING SPLICING OF mRNA PRECURSORS 有权能够修饰mRNA前体分离的ENA核酸药物公开(公告)号：US20140316123A1
公开(公告)日：2014-10-23
申请号：US14258663
申请日：2014-04-22
申请人： Masafumi Matsuo , Yasuhiro Takeshima , DAIICHI SANKYO COMPANY, LIMITED , Makoto Koizumi , Orphan Disease Treatment Institute Co., Ltd.
IPC分类号： C12N15/113
CPC分类号： C07H21/04 , A61K38/00 , A61K48/00 , C12N15/113 , C12N2310/11 , C12N2310/3231 , C12N2320/33
摘要： Oligonucleotides having a nucleotide sequence complementary to nucleotide numbers such as 2571-2607, 2578-2592, 2571-2592, 2573-2592, 2578-2596, 2578-2601 or 2575-2592 of the dystrophin cDNA (Gene Bank accession No. NM_004006.1) and therapeutic agents for muscular dystrophy comprising such oligonucleotides.
摘要翻译： 具有与核苷酸序列互补的核苷酸序列的寡核苷酸，例如抗肌萎缩蛋白cDNA（Gene Bank登录号NM_004006）的2571-2607,2578-2592,2571-2592,2573-2592,2578-2596,2578-2601或2575-2592。 1）和包含这种寡核苷酸的肌营养不良的治疗剂。
-
4.发明申请ENA NUCLEIC ACID PHARMACEUTICALS CAPABLE OF MODIFYING SPLICING OF mRNA PRECURSORS 有权能够修饰mRNA前体分离的ENA核酸药物公开(公告)号：US20130090465A1
公开(公告)日：2013-04-11
申请号：US13673466
申请日：2012-11-09
IPC分类号： C07H21/04
CPC分类号： C07H21/04 , A61K38/00 , A61K48/00 , C12N15/113 , C12N2310/11 , C12N2310/3231 , C12N2320/33
摘要： Oligonucleotides having a nucleotide sequence complementary to nucleotide numbers such as 2571-2607, 2578-2592, 2571-2592, 2573-2592, 2578-2596, 2578-2601 or 2575-2592 of the dystrophin cDNA (Gene Bank accession No. NM_004006.1) and therapeutic agents for muscular dystrophy comprising such oligonucleotides.
摘要翻译： 具有与核苷酸序列互补的核苷酸序列的寡核苷酸，例如抗肌萎缩蛋白cDNA（Gene Bank登录号NM_004006）的2571-2607,2578-2592,2571-2592,2573-2592,2578-2596,2578-2601或2575-2592。 1）和包含这种寡核苷酸的肌营养不良的治疗剂。
-
公开(公告)号：US08624019B2
公开(公告)日：2014-01-07
申请号：US12847237
申请日：2010-07-30
CPC分类号： C07H21/04 , A61K38/00 , A61K48/00 , C12N15/113 , C12N2310/11 , C12N2310/3231 , C12N2320/33
摘要： Oligonucleotides having a nucleotide sequence complementary to nucleotide numbers such as 2571-2607, 2578-2592, 2571-2592, 2573-2592, 2578-2596, 2578-2601 or 2575-2592 of the dystrophin cDNA (Gene Bank accession No. NM_004006.1) and therapeutic agents for muscular dystrophy comprising such oligonucleotides.
摘要翻译： 具有与核苷酸序列互补的核苷酸序列的寡核苷酸，例如抗肌萎缩蛋白cDNA（Gene Bank登录号NM_004006）的2571-2607,2578-2592,2571-2592,2573-2592,2578-2596,2578-2601或2575-2592。 1）和包含这种寡核苷酸的肌营养不良的治疗剂。
-
公开(公告)号：US07902160B2
公开(公告)日：2011-03-08
申请号：US10536258
申请日：2003-11-21
CPC分类号： C07H21/04 , A61K38/00 , A61K48/00 , C12N15/113 , C12N2310/11 , C12N2310/3231 , C12N2320/33
摘要： Oligonucleotides having a nucleotide sequence complementary to nucleotide numbers such as 2571-2607, 2578-2592, 2571-2592, 2573-2592, 2578-2596, 2578-2601 or 2575-2592 of the dystrophin cDNA (Gene Bank accession No. NM_004006.1) and therapeutic agents for muscular dystrophy comprising such oligonucleotides.
摘要翻译： 具有与核苷酸序列互补的核苷酸序列的寡核苷酸，例如抗肌萎缩蛋白cDNA（Gene Bank登录号NM_004006）的2571-2607,2578-2592,2571-2592,2573-2592,2578-2596,2578-2601或2575-2592。 1）和包含这种寡核苷酸的肌营养不良的治疗剂。
-
7.发明授权ENA nucleic acid pharmaceuticals capable of modifying splicing of mRNA precursors 有权能够修饰mRNA前体剪接的ENA核酸药物公开(公告)号：US09243026B2
公开(公告)日：2016-01-26
申请号：US14258663
申请日：2014-04-22
申请人： DAIICHI SANKYO COMPANY, LIMITED , Masafumi Matsuo , Yasuhiro Takeshima , Orphan Disease Treatment Institute Co., Ltd.
IPC分类号： C07H21/04 , C12N15/113 , A61K38/00 , A61K48/00
CPC分类号： C07H21/04 , A61K38/00 , A61K48/00 , C12N15/113 , C12N2310/11 , C12N2310/3231 , C12N2320/33
摘要： Oligonucleotides having a nucleotide sequence complementary to nucleotide numbers such as 2571-2607, 2578-2592, 2571-2592, 2573-2592, 2578-2596, 2578-2601 or 2575-2592 of the dystrophin cDNA (Gene Bank accession No. NM_004006.1) and therapeutic agents for muscular dystrophy comprising such oligonucleotides.
摘要翻译： 具有与核苷酸序列互补的核苷酸序列的寡核苷酸，例如抗肌萎缩蛋白cDNA（Gene Bank登录号NM_004006）的2571-2607,2578-2592,2571-2592,2573-2592,2578-2596,2578-2601或2575-2592。 1）和包含这种寡核苷酸的肌营养不良的治疗剂。
-
公开(公告)号：US20160002636A1
公开(公告)日：2016-01-07
申请号：US14858404
申请日：2015-09-18
申请人： Masafumi Matsuo , Yasuhiro Takeshima , Daiichi Sankyo Company, Limited , Orphan Disease Treatment Institute Co., Ltd.
IPC分类号： C12N15/113
CPC分类号： C07H21/04 , A61K38/00 , A61K48/00 , C12N15/113 , C12N2310/11 , C12N2310/3231 , C12N2320/33
摘要： Oligonucleotides having a nucleotide sequence complementary to nucleotide numbers such as 2571-2607, 2578-2592, 2571-2592, 2573-2592, 2578-2596, 2578-2601 or 2575-2592 of the dystrophin cDNA (Gene Bank accession No. NM_004006.1) and therapeutic agents for muscular dystrophy comprising such oligonucleotides.
-
公开(公告)号：US09657050B2
公开(公告)日：2017-05-23
申请号：US14858404
申请日：2015-09-18
申请人： DAIICHI SANKYO COMPANY, LIMITED , Masafumi Matsuo , Yasuhiro Takeshima , Orphan Disease Treatment Institute Co., Ltd.
IPC分类号： C07H21/02 , C07H21/04 , C12N15/113 , A61K38/00 , A61K48/00
CPC分类号： C07H21/04 , A61K38/00 , A61K48/00 , C12N15/113 , C12N2310/11 , C12N2310/3231 , C12N2320/33
摘要： Oligonucleotides having a nucleotide sequence complementary to nucleotide numbers such as 2571-2607, 2578-2592, 2571-2592, 2573-2592, 2578-2596, 2578-2601 or 2575-2592 of the dystrophin cDNA (Gene Bank accession No. NM_004006.1) and therapeutic agents for muscular dystrophy comprising such oligonucleotides.
-
公开(公告)号：US06653467B1
公开(公告)日：2003-11-25
申请号：US09667327
申请日：2000-09-22
IPC分类号： C07H2104
CPC分类号： C12N15/113 , A61K38/00 , A61K48/00 , C12N2310/11 , C12N2310/315
摘要： Antisense oligonucleotides comprising a nucleotide sequence complementary to the nucleotide sequence of SEQ ID NO:1 or NO:2 are disclosed. The antisense oligonucleotides are used for treatment of specific types of Duchenne muscular dystrophy which is attributed to a change in number of the nucleotides composing one or more exons adjacent to exon 43 or 53, respectively, in human dystrophin mRNA, wherein the change is due to deletion of one or more nucleotides from the normal nucleotide sequence for the exons, wherein the net of the change in number of the nucleotides is expressed as a reduction of (3×N+1) nucleotides, wherein N is zero or a natural number.
摘要翻译： 公开了包含与SEQ ID NO：1或NO：2的核苷酸序列互补的核苷酸序列的反义寡核苷酸。 反义寡核苷酸用于治疗特定类型的Duchenne肌营养不良症，其归因于构成人肌营养不良蛋白mRNA中分别与外显子43或53相邻的一个或多个外显子的核苷酸数量的变化，其中变化是由于 从外显子的正常核苷酸序列中删除一个或多个核苷酸，其中核苷酸数量变化的净值表示为（3×N + 1）核苷酸的减少，其中N为零或自然数。
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.03 秒)